

Form 1449*	Atty. Docket No.: 1036.031US3	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Timothy L. Macdonald	
	Filing Date: Herewith	Group: Unknown

10/02/05
12/17/01

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>ms</i>	2,884,444	04/28/1959	Berger, F.M., et al.	260	482	01/13/56
<i>ms</i>	4,868,327	09/19/1989	Stiefel, F.J.	560	164	06/03/87
<i>ms</i>	4,978,680	12/18/1990	Sofia, R.D.	514	534	09/26/89
<i>ms</i>	5,055,489	10/08/1991	Sofia, R.D.	514	483	05/04/90
<i>ms</i>	5,082,861	01/21/1992	Sofia, R.D.	514	534	12/07/90
<i>ms</i>	5,292,772	03/08/1994	Sofia, R.D.	514	534	10/26/92
<i>ms</i>	5,462,966	10/31/1995	Sofia, R.D.	514	483	10/15/93

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
-----------------------	-----------------	------	---------	-------	----------	-----------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
<i>ms</i>	Choi, Y.M., et al., "Metabolites of Felbamate: Synthesis of 2-(4-Hydroxyphenyl)-1,3-Propanediol Dicarbamate, 2-Phenyl-2-Hydroxy-1,3-Propanediol Dicarbamate, and 2-Phenyl-1,3-Propanediol Monocarbamate", <u>Tetrahedron</u> , 42 (23), pp. 6399-6404, (1986)
<i>ms</i>	O'Neal, M.G., et al., "Felbamate-associated fatal acute hepatic necrosis", <u>Neurology</u> , 46, pp. 1457-1459, (May 1996)
<i>ms</i>	Pennell, P.B., et al., "Aplastic anemia in a patient receiving felbamate for complex partial seizures", <u>Neurology</u> , 45, pp. 456-460, (March 1995)

Examiner

Matthew Bryant

Date Considered

3/7/07

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



#9

Sheet 1 of 1

Form 1449*	Atty. Docket No.: 1036.031US3	Serial No. 10/023,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Timothy L. Macdonald	
	Filing Date: December 17, 2001	Group: Unknown

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>js</i>	5,492,930	02/20/1996	Coffin, V.L.	514	478	04/25/94

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
-----------------------	-----------------	------	---------	-------	----------	-------------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
<i>js</i>	Adusumalli, V.E., et al., "Isolation and Identification of 3-Carbamoyloxy-2-Phenylpropionic Acid as a Major Human Urinary Metabolite of Felbamate", <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Vol. 21, pp. 710-716, (1993)
<i>js</i>	Burdette, D.E., et al., "Felbamate Pharmacology and Use in Epilepsy", <u>Clinical Neuropharmacology</u> , Vol. 17, No. 5, pp. 389-402, (1994)
<i>js</i>	Kapetanovic, I.M., et al., "Potentially Reactive Cyclic Carbamate Metabolite of the Antiepileptic Drug Felbamate Produced by Human Liver Tissue In Vitro", <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Vol. 26, No. 11, pp. 1089-1095, (1998)
<i>js</i>	Kaufman, D.W., "Evaluation of Case Reports of Aplastic Anemia Among Patients Treated with Felbamate", <u>Epilepsia</u> , 38 (12), pp. 1265-1269, (1997)
<i>js</i>	Schmidt, D., "Felbamate: Successful Development of a New Compound for the Treatment of Epilepsy", <u>Epilepsia</u> , 34 (Suppl. 7), pp. S30-S33, (1993)
<i>js</i>	Shuaib, A., et al., "Neuroprotection With Felbamate: A 7- and 28-Day Study in Transient Forebrain Ischemia in Gerbils", <u>Brain Research</u> 727, pp. 65-70, (1996)
<i>js</i>	Sofia, R.D., "Mechanism of Action of the Anticonvulsant Felbamate: Opposing Effects on N-Methyl-D-Aspartate and γ -Aminobutyric Acid Receptors", <u>American Neurological Association</u> , pp. 677-678, (1994)
<i>js</i>	Wamsley, J.K., et al., "Interaction of Felbamate with [3 H]DCKA-Labeled Strychnine-Insensitive Glycine Receptors in Human Postmortem Brain", <u>Experimental Neurology</u> 129, pp. 244-250, (1994)
<i>js</i>	Yang, J.T., et al., "Felbamate Metabolism in the Rat, Rabbit, and Dog", <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Vol. 19, No. 6, pp. 1126-1134, (1991)

Examiner

hath B/ob

Date Considered

3/7/03

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


#10

Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Sheet 1 of 1

Complete if Known

Application Number 10/023059

Filing Date December 17, 2001

First Named Inventor Macdonald, Timothy

Group Art Unit 1614

Examiner Name Unknown

RECEIVED

SEP 12 2002

TECH CENTER 1600/2900

Attorney Docket No: 01036.031US3

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
8/2	WO-94/06737	03/31/1994	Walker, D. , et al	C07 C	29/147	—

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
--------------------	----------------------	---	----------------


EXAMINER

DATE CONSIDERED

3/2/03

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



12

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/023059
Filing Date	December 17, 2001
First Named Inventor	Macdonald, Timothy
Group Art Unit	1614
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 1036.031US3

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
mc	EP-97/37652	10/16/1997	Kozachuk, Walter E	—	—	—

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mc		KNIGHT, J..L. ,et al. , "A Computational Quantitative Structure - Activity Relationship Study of Carbamate Anticonvulsants Using Quantum Pharmacological Methods", <u>Seizure</u> , (1998),347-354	
mc		SHEILDS, W..D. , "Investigational Antiepileptic Drugs for the Treatment of Childhood Seizure Disorders: a Review of Efficacy and Safety", <u>Epilepsia</u> , (1994),24-29 (ABSTRACT ONLY)	

EXAMINER

DATE CONSIDERED

8/7/03

Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached